查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1587848

半固態CDMO 市場規模、佔有率和趨勢分析報告：按管理途徑、產品、服務、最終用途、國家和細分市場進行預測，2024-2030 年

Semi-Solid Dosage CDMO Market Size, Share & Trends Analysis Report By Route of Administration (Topical, Transdermal, Others), By Product, By Service, By End Use, By Country, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 140 Pages | 商品交期: 2-10個工作天內

價格

半固態CDMO 市場成長與趨勢：

根據Grand View Research, Inc.最新報告，預計到2030年，全球半固態CDMO市場將達到674億美元，2024年至2030年複合年成長率為11.80%。

全球半固態CDMO 市場規模是由個人化醫療的成長趨勢以及對創新藥物輸送系統不斷成長的需求所推動的。乳膏、凝膠和軟膏等固態製劑因其易於塗布和快速吸收而受到患者的青睞。此外，它在皮膚科治療中廣泛採用，以增加患者的治療選擇。根據美國皮膚病學會協會 2024 年 9 月發布的資料，痤瘡是最常見的疾病，每年影響美國約 5,000 萬人。而且，其中85%的人年齡在12歲至24歲之間。因此，皮膚病患病率的不斷上升導致對外用製劑開發的需求增加，從而推動對 CDMO 擴大其半固態製劑能力的需求。

此外，製劑和製造流程的持續技術進步也推動了半固態藥物市場的發展。奈米技術和先進乳化技術等創新正在提高固態製劑的功效和穩定性。這些進步使 CDMO 能夠生產滿足嚴格監管要求的高品質產品，從而吸引更多客戶。例如，乳化的開發提高了活性成分的生物有效性，使固態製劑能夠更有效地用於治療慢性疼痛和發炎疾病等各種病症。

此外，慢性病盛行率的增加以及人口老化也促進了半固態CDMO 市場的成長。隨著越來越多的人尋求關節炎、糖尿病和皮膚病等疾病的治療，預計未來幾年對有效半固態製劑的需求將會增加。這種趨勢在老年醫學中尤其明顯，固態製劑因其易於使用而通常受到青睞。因此，這些因素進一步促進了市場的成長。

固態CDMO 市場報告亮點

  • 從產品來看，外用製劑將在2023年佔據市場主導地位，佔有率為88.48%。這些製劑對於局部治療特別有效，是皮膚科應用的理想選擇。
  • 從給藥途徑來看，2023 年乳霜和乳液佔據市場主導地位。這些配方具有獨特的優點，例如易於塗布、質地宜人、改善皮膚吸收，有助於該細分市場的成長。
  • 按服務分類，契約製造製造業在 2023 年銷售額中所佔佔有率最大。為了專注於研發等核心能力，製藥公司擴大將其製造流程委託給 CDMO。
  • 以最終用途分類，製藥公司細分市場在 2023 年佔據最大收益佔有率。這是由於對創新治療解決方案的需求增加導致公司增加了對開發新藥的投資。
  • 2023年，北美市場佔據主導地位，佔有率為41.12%。該地區慢性病患病率的上升以及對先進治療解決方案的需求不斷增加正在推動市場擴張。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章半固態CDMO市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 半固態CDMO市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • COVID-19 影響分析

第4章半固態CDMO市場：給藥途徑預估及趨勢分析

  • 按管理途徑分類的半固態CDMO 市場：細分儀表板
  • 半固態CDMO 市場，依管理途徑：變化分析
  • 依途徑，2018-2030
    • 外用
    • 經皮的
    • 其他

第5章 半固態CDMO市場：產品預估及趨勢分析

  • 半固態CDMO 市場，副產品：細分儀表板
  • 半固態CDMO市場，依產品：變化分析
  • 按產品分類，2018-2030
    • 軟膏
    • 霜和乳液
    • 貼上
    • 凝膠
    • 其他

第6章 半固態CDMO市場：服務評估與趨勢分析

  • 半固態CDMO 市場，依服務分類：細分儀表板
  • 半固態CDMO市場，按服務：波動分析
  • 按服務分類，2018-2030
    • 合約開發
    • 契約製造

第7章 半固態CDMO市場：最終用途估算與趨勢分析

  • 半固態CDMO 市場，依最終用途：細分儀表板
  • 半固態CDMO 市場，依最終用途：變化分析
  • 按最終用途分類，2018-2030
    • 製藥公司
    • 生物製藥公司
    • 其他

第8章 半固態CDMO市場：區域估算及趨勢分析

  • 2023 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場簡介
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 瑞典
    • 丹麥
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 泰國
    • 韓國
    • 澳洲
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 市場參與企業分類
    • 創新者
    • 市場領導者
    • 新興玩家
  • 2023 年公司市場佔有率/地位分析
  • 公司簡介
    • The Lubrizol Corporation
    • Cambrex Corporation
    • Contract Pharmaceuticals Limited.
    • Bora Pharmaceutical
    • Ascendia Pharmaceuticals
    • Pierre Fabre group
    • Piramal Pharma Solutions
    • DPT Laboratories, LTD
    • LGM Pharma
    • Pace Analytical Life Sciences, LLC.
Product Code: GVR-4-68040-477-4

Semi-Solid Dosage CDMO Market Growth & Trends:

The global semi-solid Dosage CDMO market is expected to reach USD 67.4 billion by 2030, and anticipated to grow at a CAGR of 11.80% from 2024 to 2030 according to a new report by Grand View Research, Inc. The global semi-solid dosage CDMO market size is driven due to growing trend towards personalized medicine coupled with increasing demand for innovative drug delivery systems. Patients prefer semi-solid formulations, such as creams, gels, and ointments, due to their ease of application and rapid absorption. Moreover, it has significant adoption for dermatological treatments to enhance patient treatment options. According to the data published by the American Academy of Dermatology Association in September 2024, Acne is the most common condition affecting approximately 50 million people in the U.S. annually. Moreover, 85% of the people are among age 12 to 24. Thus, increasing prevalence of skin disorders has led to an increasing demand for the development of topical formulations, consequently driving the demand for CDMOs to expand their capabilities in semi-solid dosage forms.

Furthermore, constant technological advancements in formulation and manufacturing processes have also propelled the semi-solid dosage market. Innovations such as nanotechnology and advanced emulsion techniques have improved the efficacy and stability of semi-solid formulations. These advancements enable CDMOs to produce high-quality products that meet stringent regulatory requirements, thereby attracting more clients. For instance, the development of nano-emulsions has enhanced the bioavailability of active ingredients, making semi-solid formulations more effective in treating various conditions, including chronic pain and inflammatory diseases.

In addition, increasing prevalence of chronic diseases, coupled with an aging population, is also contributing to the growth of the semi-solid dosage CDMO market. As more individuals seek treatments for conditions such as arthritis, diabetes, and skin disorders, the demand for effective semi-solid formulations is projected to increase in the coming years. This trend is particularly prominent in geriatric care, where semi-solid forms are often preferred due to their ease of use. Thus, these factors are further contributing to the market growth.

Semi-Solid Dosage CDMO Market Report Highlights:

  • Based on product, topical segment dominated in the market with a share of 88.48% in 2023. These formulations are particularly effective for localized treatments, making them ideal for dermatological applications
  • Based on rout of administration, creams and lotions dominated the market in 2023. These formulations offer unique benefits such as ease of application, pleasant texture, and enhanced skin absorption which is contributing to the segment's growth
  • Based on service, the contract manufacturing segment accounted for the largest revenue share in 2023. Pharmaceutical companies are increasingly outsourcing their manufacturing processes to CDMOs to focus on core competencies such as research and development
  • Based on end use, the pharmaceutical companies segment accounted for the largest revenue share in 2023 owing to the increasing demand for innovative therapeutic solutions which has resulted into the increasing investment by the companies for the development of new drugs
  • North America dominated the market with a share of 41.12% in 2023. The increasing prevalence of chronic diseases and increasing demand for advanced therapeutic solutions in the region are propelling market expansion

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Route of Administration
    • 1.2.2. Product
    • 1.2.3. Service
    • 1.2.4. End Use
  • 1.3. Regional Scope
  • 1.4. Estimates And Forecast Timeline
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
    • 1.9.2. Parent Market Analysis
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Semi-Solid Dosage CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Semi-Solid Dosage CDMO Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Semi-Solid Dosage CDMO Market: Route of Administration Estimates & Trend Analysis

  • 4.1. Semi-Solid Dosage CDMO Market, By Route of Administration: Segment Dashboard
  • 4.2. Semi-Solid Dosage CDMO Market, By Route of Administration: Movement Analysis
  • 4.3. Semi-Solid Dosage CDMO Market Estimates & Forecasts, By Route of Administration, 2018 - 2030
    • 4.3.1. Topical
      • 4.3.1.1. Topical Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
    • 4.3.2. Transdermal
      • 4.3.2.1. Transdermal Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
    • 4.3.3. Others
      • 4.3.3.1. Others Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)

Chapter 5. Semi-Solid Dosage CDMO Market: Product Estimates & Trend Analysis

  • 5.1. Semi-Solid Dosage CDMO Market, By Product: Segment Dashboard
  • 5.2. Semi-Solid Dosage CDMO Market, By Product: Movement Analysis
  • 5.3. Semi-Solid Dosage CDMO Market Estimates & Forecasts, By Product, 2018 - 2030
    • 5.3.1. Ointments
      • 5.3.1.1. Ointments Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
    • 5.3.2. Creams and Lotions
      • 5.3.2.1. Creams and Lotions Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
    • 5.3.3. Pastes
      • 5.3.3.1. Pastes Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
    • 5.3.4. Gels
      • 5.3.4.1. Gels Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
    • 5.3.5. Others
      • 5.3.5.1. Others Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)

Chapter 6. Semi-Solid Dosage CDMO Market: Service Estimates & Trend Analysis

  • 6.1. Semi-Solid Dosage CDMO Market, By Service: Segment Dashboard
  • 6.2. Semi-Solid Dosage CDMO Market, By Service: Movement Analysis
  • 6.3. Semi-Solid Dosage CDMO Market Estimates & Forecasts, By Service, 2018 - 2030
    • 6.3.1. Contract Development
      • 6.3.1.1. Contract Development Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
    • 6.3.2. Contract Manufacturing
      • 6.3.2.1. Contract Manufacturing Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)

Chapter 7. Semi-Solid Dosage CDMO Market: End Use Estimates & Trend Analysis

  • 7.1. Semi-Solid Dosage CDMO Market, By End Use: Segment Dashboard
  • 7.2. Semi-Solid Dosage CDMO Market, By End Use: Movement Analysis
  • 7.3. Semi-Solid Dosage CDMO Market Estimates & Forecasts, By End Use, 2018 - 2030
    • 7.3.1. Pharmaceutical Companies
      • 7.3.1.1. Pharmaceutical Companies Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
    • 7.3.2. Biopharmaceutical Companies
      • 7.3.2.1. Biopharmaceutical Companies Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
    • 7.3.3. Others
      • 7.3.3.1. Others Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)

Chapter 8. Semi-Solid Dosage CDMO Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2023 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. North America
    • 8.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Canada Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Mexico Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.5. Europe
    • 8.5.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. UK Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Germany Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. France Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Competitive Scenario
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Italy Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Competitive Scenario
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Spain Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.5.7. Sweden
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Competitive Scenario
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Sweden Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.5.8. Denmark
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Competitive Scenario
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Denmark Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Competitive Scenario
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Norway Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.6. Asia Pacific
    • 8.6.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Japan Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. China Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. India Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.6.5. Thailand
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Thailand Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Competitive Scenario
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. South Korea Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.6.7. Australia
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Competitive Scenario
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Australia Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.7. Latin America
    • 8.7.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Competitive Scenario
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Brazil Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Competitive Scenario
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Argentina Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.8. MEA
    • 8.8.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Competitive Scenario
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. South Africa Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Competitive Scenario
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Saudi Arabia Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Competitive Scenario
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. UAE Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Competitive Scenario
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Kuwait Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
    • 9.1.1. Innovators
    • 9.1.2. Market Leaders
    • 9.1.3. Emerging Players
  • 9.2. Company Market Share/Position Analysis, 2023
  • 9.3. Company Profiles
    • 9.3.1. The Lubrizol Corporation
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Service Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Cambrex Corporation
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Service Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Contract Pharmaceuticals Limited.
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Service Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Bora Pharmaceutical
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Service Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Ascendia Pharmaceuticals
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Service Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Pierre Fabre group
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Service Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. Piramal Pharma Solutions
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Service Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. DPT Laboratories, LTD
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Service Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. LGM Pharma
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Service Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. Pace Analytical Life Sciences, LLC.
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Service Benchmarking
      • 9.3.10.4. Strategic Initiatives

List of Tables

  • Table 1. List of Tables
  • Table 2. List of Secondary Sources
  • Table 3. List of Abbreviations
  • Table 4. Global Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 5. Global Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 6. Global Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 7. Global Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 8. Global Semi-Solid Dosage CDMO, by Region, 2018 - 2030 (USD Million)
  • Table 9. North America Semi-Solid Dosage CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 10. North America Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 11. North America Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 12. North America Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 13. North America Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 14. U.S. Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 15. U.S. Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 16. U.S. Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 17. U.S. Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 18. Canada Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 19. Canada Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 20. Canada Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 21. Canada Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 22. Mexico Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 23. Mexico Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 24. Mexico Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 25. Mexico Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 26. Europe Semi-Solid Dosage CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 27. Europe Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 28. Europe Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 29. Europe Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 30. Europe Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 31. UK Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 32. UK Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 33. UK Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 34. UK Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 35. Germany Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 36. Germany Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 37. Germany Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 38. Germany Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 39. France Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 40. France Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 41. France Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 42. France Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 43. Italy Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 44. Italy Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 45. Italy Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 46. Italy Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 47. Spain Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 48. Spain Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 49. Spain Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 50. Spain Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 51. Denmark Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 52. Denmark Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 53. Denmark Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 54. Denmark Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 55. Sweden Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 56. Sweden Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 57. Sweden Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 58. Sweden Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 59. Norway Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 60. Norway Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 61. Norway Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 62. Norway Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 63. Asia Pacific Semi-Solid Dosage CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 64. Asia Pacific Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 65. Asia Pacific Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 66. Asia Pacific Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 67. Asia Pacific Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 68. Japan Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 69. Japan Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 70. Japan Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 71. Japan Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 72. China Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 73. China Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 74. China Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 75. China Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 76. India Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 77. India Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 78. India Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 79. India Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 80. Thailand Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 81. Thailand Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 82. Thailand Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 83. Thailand Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 84. South Korea Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 85. South Korea Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 86. South Korea Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 87. South Korea Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 88. Australia Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 89. Australia Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 90. Australia Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 91. Australia Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 92. Latin America Semi-Solid Dosage CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 93. Latin America Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 94. Latin America Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 95. Latin America Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 96. Latin America Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 97. Brazil Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 98. Brazil Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 99. Brazil Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 100. Brazil Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 101. Argentina Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 102. Argentina Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 103. Argentina Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 104. Argentina Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 105. Middle East & Africa Semi-Solid Dosage CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 106. Middle East & Africa Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 107. Middle East & Africa Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 108. Middle East & Africa Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 109. Middle East & Africa Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 110. South Africa Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 111. South Africa Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 112. South Africa Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 113. South Africa Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 114. Saudi Arabia Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 115. Saudi Arabia Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 116. Saudi Arabia Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 117. Saudi Arabia Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 118. UAE Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 119. UAE Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 120. UAE Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 121. UAE Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 122. Kuwait Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 123. Kuwait Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 124. Kuwait Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 125. Kuwait Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Semi-Solid Dosage CDMO Market revenue, 2018-2030 (USD Million)
  • Fig. 10 Semi-Solid Dosage CDMO Market snapshot
  • Fig. 11 Semi-Solid Dosage CDMO Market driver impact
  • Fig. 12 Semi-Solid Dosage CDMO Market restraint impact
  • Fig. 13 Semi-Solid Dosage CDMO sector Route of administration takeaways (USD Million)
  • Fig. 14 Semi-Solid Dosage CDMO Market: Route of administration movement analysis
  • Fig. 15 Topical market, 2018 - 2030 (USD Million)
  • Fig. 16 Transdermal market, 2018 - 2030 (USD Million)
  • Fig. 17 Others market, 2018 - 2030 (USD Million)
  • Fig. 18 Semi-Solid Dosage CDMO sector Product takeaways (USD Million)
  • Fig. 19 Semi-Solid Dosage CDMO Market: Product movement analysis
  • Fig. 20 Ointments market, 2018 - 2030 (USD Million)
  • Fig. 21 Creams and Lotions market, 2018 - 2030 (USD Million)
  • Fig. 22 Pastes market, 2018 - 2030 (USD Million)
  • Fig. 23 Gels market, 2018 - 2030 (USD Million)
  • Fig. 24 Others market, 2018 - 2030 (USD Million)
  • Fig. 25 Semi-Solid Dosage CDMO sector Service takeaways (USD Million)
  • Fig. 26 Semi-Solid Dosage CDMO Market: Service movement analysis
  • Fig. 27 Contract Development market, 2018 - 2030 (USD Million)
  • Fig. 28 Contract Manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 29 Semi-Solid Dosage CDMO sector End Use takeaways (USD Million)
  • Fig. 30 Semi-Solid Dosage CDMO Market: End Use movement analysis
  • Fig. 31 Pharmaceutical Companies market, 2018 - 2030 (USD Million)
  • Fig. 32 Biopharmaceutical Companies market, 2018 - 2030 (USD Million)
  • Fig. 33 Others market, 2018 - 2030 (USD Million)
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 Regional outlook, 2023 & 2030
  • Fig. 36 North America Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 37 U.S. Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 38 Canada Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 39 Mexico Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 40 Europe Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 41 UK Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 42 Germany Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 43 France Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 44 Italy Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 45 Spain companion animal Health market, 2018 - 2030 (USD Million)
  • Fig. 46 Sweden Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 47 Denmark Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 48 Norway Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 49 Asia Pacific Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 50 Japan Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 51 China Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 52 India Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 53 Thailand Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 54 South Korea Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 55 Australia Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 56 Latin America Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 57 Brazil Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 58 Argentina Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 59 Middle East & Africa Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 60 South Africa Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 61 Saudi Arabia Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 62 UAE Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 63 Kuwait Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 64 Market participant categorization